DPA-714-PET/MRI for Parkinson's Disease

Phase-Based Progress Estimates
Parkinson's DiseaseDPA-714-PET/MRI - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will measure the level of neuroinflammation in the brains of people with Parkinson's disease compared to healthy controls, using a PET scan with the tracer [18F]DPA-714.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 2 years

2 years
Comparison of TSPO-PET measures of neuroinflammation between PD patients and healthy controls.
Correlation of DPA-714-PET/MRI with demographics, clinical and biospecimen assessments from Neuroinflammation in PD study

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Healthy Controls, DPA-714-PET/MRI
1 of 2
Early Parkinson's Disease, DPA-714-PET/MRI
1 of 2

Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: DPA-714-PET/MRI · No Placebo Group · Phase 1 & 2

Healthy Controls, DPA-714-PET/MRI
Experimental Group · 1 Intervention: DPA-714-PET/MRI · Intervention Types: Drug
Early Parkinson's Disease, DPA-714-PET/MRI
Experimental Group · 1 Intervention: DPA-714-PET/MRI · Intervention Types: Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,434 Previous Clinical Trials
2,229,192 Total Patients Enrolled
Jonathan McConathy, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
2 Previous Clinical Trials
180 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a participant in the UAB Neuroinflammation in PD study
You are post-menopausal with at least 1 year since last menses or documented surgical sterilization.
You have a high or mixed affinity for TSPO ligands based on genotyping for SNP rs6971.